J.C.-H. Yang

499 citations

12 papers · 353 indexed · 1 hit paper · h-index 5

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 11
- Lung Cancer Research Studies 9
- Cancer Immunotherapy and Biomarkers 3
- HER2/EGFR in Cancer Research 2
- Cancer Treatment and Pharmacology 1
- Colorectal Cancer Treatments and Studies 1
Pulmonary and Respiratory Medicine 10
- Lung Cancer Treatments and Mutations 10

Co-authors: Suresh S. Ramalingam (1 shared paper)Melanie M. Frigault (1 shared paper)Helen Mann (1 shared paper)Geoffrey R. Oxnard (1 shared paper)Kenneth S. Thress (1 shared paper)Leora Horn (1 shared paper)Seung‐Whan Kim (1 shared paper)Kōichi Goto (1 shared paper)
Journals: Annals of Oncology (10 papers)Journal of Thoracic Oncology (1 paper)The Chinese-German Journal of Clinical Oncology (1 paper)
Partner nations: Taiwan United States Canada

In The Last Decade

J.C.-H. Yang

12 papers receiving 351 citations

Hit Papers

align trajectories log scale

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer 2020 · 303 citations

Peers

Countries citing papers authored by J.C.-H. Yang

Since Specialization

Citations

This map shows the geographic impact of J.C.-H. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C.-H. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C.-H. Yang more than expected).

Fields of papers citing papers by J.C.-H. Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C.-H. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C.-H. Yang. The network helps show where J.C.-H. Yang may publish in the future.

Co-authors

The 25 scholars most cited alongside J.C.-H. Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.C.-H. Yang Line = papers co-authored together J.C.-H. Yang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work
1	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer Annals of Oncology ·Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn Hit paper breakdown →	2020	303
2	Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7 Annals of Oncology ·Lecia V. Sequist, Yi‐Long Wu, Martin Schüler, Terufumi Kato, J.C.-H. Yang, Hiroshi Tanaka, Toyoaki Hida, Shun Lü, K. Park, Scott A. Laurie, Jaafar Bennouna, D. Moro Sibilot, Angela Märten, Barbara Peil, E. Ehrnrooth, Nobuyuki Yamamoto, Kazuhiko Nakagawa	2017	10
3	Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) Annals of Oncology ·Luis Paz‐Ares, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, J.C.-H. Yang, Tony Mok, K.H. Lee, Shun Lü, Yuankai Shi, Soo Wan Kim, Janessa Laskin, Dongwook Kim, Scott A. Laurie, Karl Kölbeck, Jean Fan, Nigel Dodd, Angela Märten, K. Park	2016	9
4	Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G Annals of Oncology ·Corey J. Langer, S.M. Gaddgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, J.C.-H. Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi	2016	8
5	1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC Annals of Oncology ·Hye Ryun Kim, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, M. Wollner, J.C.-H. Yang, Julien Mazières, F. Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yun Luo, Melissa L. Santorelli, M. Catherine Pietanza, Charles M. Rudin	2020	4
6	12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs Annals of Oncology ·S-G. Wu, C-C. Ho, J.C.-H. Yang, B-C. Liao, C-Y. Yang, Yu‐Tsan Lin, Chong‐Jen Yu, Wei‐Yu Liao, J-Y. Shih	2022	4
7	Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ) Annals of Oncology ·Sanjay Popat, G. Liu, Shun Lü, Gregory Song, Vivek Samnotra, J.C.-H. Yang	2019	4
8	185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03) Journal of Thoracic Oncology ·David Planchard, J.C.-H. Yang, Julie R. Brahmer, Angela Ragone, J. Chen, F. Liu, Matilde Saggese	2021	3
9	Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC) Annals of Oncology ·Fabrice Barlési, Mustafa Özgüroğlu, Johan Vansteenkiste, David R. Spigel, J.C.-H. Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, K. Park	2019	3
10	Expression of the Glypican-3 Gene in α-fetoprotein-negative Human Hepatocellular Carcinoma The Chinese-German Journal of Clinical Oncology ·Guanghui Ding, Hongyang Wang, Han Chen, Meng‐Chao Wu, Xiaobo Man, Wen‐Ming Cong, J.C.-H. Yang, Shuqun Cheng, Nan Li, Li Shen	2005	2
11	KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) Annals of Oncology ·Martin Gutierrez, Wei‐Sen Lam, Matthew D. Hellmann, Matthew A. Gubens, Charu Aggarwal, Daniel S.W. Tan, Enriqueta Felip, Joanne Chiu, Jun S. Lee, J.C.-H. Yang, Edward B. Garon, Andrea Basso, Hua Ma, Lawrence Fong, Alexandra Snyder, Jianda Yuan, Roy S. Herbst	2019	2
12	Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial Annals of Oncology ·Martin Schüler, E.H. Tan, Kenneth J. O’Byrne, L. Zhang, Michael Boyer, Tony Mok, Vera Hirsh, J.C.-H. Yang, K.H. Lee, S. Lu, Yan Shi, Soo Wan Kim, Janessa Laskin, Dongwook Kim, Catherine Dubos Arvis, Karl Kölbeck, Dan Massey, Jean Fan, Luis Paz‐Ares, K. Park	2016	1

About J.C.-H. Yang

J.C.-H. Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Genetics and Molecular Biology, having authored 12 papers that have together received 353 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer therapeutics and mechanisms (3 papers), HER2/EGFR in Cancer Research (2 papers), Cancer Treatment and Pharmacology (1 paper), Hepatocellular Carcinoma Treatment and Prognosis (1 paper) and Colorectal Cancer Treatments and Studies (1 paper). The work is most often cited by research in Oncology (263 citations), Pulmonary and Respiratory Medicine (281 citations), Cancer Research (46 citations), Immunology (34 citations) and Hepatology (12 citations). J.C.-H. Yang has collaborated with scholars based in Taiwan, United States and Canada. Frequent co-authors include Suresh S. Ramalingam, Melanie M. Frigault, Helen Mann, Geoffrey R. Oxnard, Kenneth S. Thress, Leora Horn, Seung‐Whan Kim, Kōichi Goto, Yuichiro Ohe and Helena A. Yu. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology and The Chinese-German Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact